StockNews.com began coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a research note published on Wednesday morning. The brokerage issued a hold rating on the biotechnology company’s stock.
Nabriva Therapeutics Price Performance
Shares of NBRV opened at $0.00 on Wednesday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 0.52 and a current ratio of 0.85. Nabriva Therapeutics has a 12-month low of $1.22 and a 12-month high of $8.45. The company has a market cap of $6,403.00, a P/E ratio of 0.00 and a beta of 1.53.
Nabriva Therapeutics Company Profile
See Also
- Five stocks we like better than Nabriva Therapeutics
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- MarketBeat Week in Review – 9/30 – 10/4
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Top Streaming Companies: Who’s Winning the Battle?
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.